Chad Gassert
Corporate Officer/Principal bei ANI PHARMACEUTICALS, INC.
Vermögen: 21 Mio $ am 31.03.2024
Profil
Chad Gassert is the founder of Novitium Pharma LLC, which was founded in 2016.
He was the Chief Executive Officer from 2016 to 2021.
Currently, he is the Senior VP-Corporate Development & Strategy at ANI Pharmaceuticals, Inc. since 2021.
Previously, he worked as Vice President-Business Development & Licensing at Endo Generics Holdings, Inc. from 2005 to 2016 and as Senior Vice President-Business Development at Par Pharmaceutical, Inc. from 2005 to 2016.
Mr. Gassert completed his undergraduate degree from the University of Delaware and his graduate degree from the New Jersey Institute of Technology.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.04.2024 | 302 905 ( 1,44% ) | 21 Mio $ | 31.03.2024 |
Aktive Positionen von Chad Gassert
| Unternehmen | Position | Beginn |
|---|---|---|
| ANI PHARMACEUTICALS, INC. | Corporate Officer/Principal | 19.11.2021 |
Ehemalige bekannte Positionen von Chad Gassert
| Unternehmen | Position | Ende |
|---|---|---|
Novitium Pharma LLC
 Novitium Pharma LLC Pharmaceuticals: OtherHealth Technology Part of ANI Pharmaceuticals, Inc., Novitium Pharma LLC is a pharmaceutical company that specializes in the development, manufacturing, and distribution of niche generic products. The private company was founded in 2016 by Muthusamy Shanmugam, Chad Gassert, and Vijay Thorappadi and is based in East Windsor, NJ, with operations also in Chennai. Novitium has a growing commercial product portfolio spanning a diverse range of dosage forms and therapeutic categories. Novitium continues to invest in producing affordable, high-quality medication to fulfill the needs of pharmacists, patients, and communities. Novitium Pharma was acquired by ANI Pharmaceuticals, Inc. on November 22, 2021 for $243.40 million. | Chief Executive Officer | 01.11.2021 |
| PAR PHARMACEUTICAL COMPANIES, INC. | Corporate Officer/Principal | 01.01.2016 |
Par Pharmaceutical, Inc.
 Par Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Par Pharmaceutical, Inc. manufactures and markets generic drugs and pharmaceuticals products. It produces drugs for hypertension, inflammation, depression and pain. The firm distributes its products in the semi-solid form of a cream. The company was founded in 1978 and is headquartered in Chestnut Ridge, NY. | Corporate Officer/Principal | 01.01.2016 |
Ausbildung von Chad Gassert
| University of Delaware | Undergraduate Degree |
| New Jersey Institute of Technology | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ANI PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Endo Generics Holdings, Inc.
 Endo Generics Holdings, Inc. Pharmaceuticals: GenericHealth Technology Endo Generics Holdings, Inc. develops, manufactures, and markets generic pharmaceutical products. It also offers dosage, branded, and generic sterile injectable products. The company was founded in 1978 and is headquartered in New York, NY. | Health Technology |
Par Pharmaceutical, Inc.
Par Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Par Pharmaceutical, Inc. manufactures and markets generic drugs and pharmaceuticals products. It produces drugs for hypertension, inflammation, depression and pain. The firm distributes its products in the semi-solid form of a cream. The company was founded in 1978 and is headquartered in Chestnut Ridge, NY. | Health Technology |
Novitium Pharma LLC
Novitium Pharma LLC Pharmaceuticals: OtherHealth Technology Part of ANI Pharmaceuticals, Inc., Novitium Pharma LLC is a pharmaceutical company that specializes in the development, manufacturing, and distribution of niche generic products. The private company was founded in 2016 by Muthusamy Shanmugam, Chad Gassert, and Vijay Thorappadi and is based in East Windsor, NJ, with operations also in Chennai. Novitium has a growing commercial product portfolio spanning a diverse range of dosage forms and therapeutic categories. Novitium continues to invest in producing affordable, high-quality medication to fulfill the needs of pharmacists, patients, and communities. Novitium Pharma was acquired by ANI Pharmaceuticals, Inc. on November 22, 2021 for $243.40 million. | Health Technology |
